Angiogenesis as a target for the treatment of ovarian cancer

Current Opinion in Oncology

Volumn 25, Issue 5, 2013, Pages 558-565

  Shaw, Danielle ^a   Clamp, Andrew ^a   Jayson, Gordon C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Angiogenesis; Angiopoietin; Ovarian cancer; VEGF

Indexed keywords

ANGIOPOIETIN; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; DOXORUBICIN; PACLITAXEL; PAZOPANIB; PLACEBO; TREBANANIB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ACIDOSIS; ANGIOGENESIS; ARTERIAL THROMBOEMBOLISM; BRAIN HEMORRHAGE; CANCER GROWTH; CANCER RESISTANCE; CANCER STAGING; DEMOGRAPHY; DRUG TARGETING; FEBRILE NEUTROPENIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOXIA; INTESTINE PERFORATION; METASTASIS; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PAIN; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; REVIEW; RNA SPLICING; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT; ANTAGONISTS AND INHIBITORS; FEMALE; MAINTENANCE CHEMOTHERAPY; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84883258022     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328363e0da     Document Type: Review

References (46)

1. Ovarian Cancer Statistics. Cancer Research UK. 2013; 2013; http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/.
2. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011; 61: 183-203.
3. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-953.
4. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinumbased treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup. J Clin Oncol 2009; 27: 1419-1425.
5. Koukourakis MI, Limberis V, Tentes I, et al. Serum VEGF levels and tissue activation of VEGFR2/KDR receptors in patients with breast and gynecologic cancer. Cytokine 2011; 53: 370-375.
6. Trinh XB, Tjalma WAA, Vermeulen PB, et al. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 2009; 100: 971-978.
7. Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors fit and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506-516.
8. Smith NR, Baker D, James NH, et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 2010; 16: 3548-3561.
9. Fraser HM, Wilson H, Morris KD, et al. Vascular endothelial growth factor Trap suppresses ovarian function at all stages of the luteal phase in the macaque. J Clin Endocrinol Metab 2005; 90: 5811-5818.
10. Robinson RS, Woad KJ, Hammond AJ, et al. Angiogenesis and vascular function in the ovary. Reproduction 2009; 138: 869-881.
11. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180-5186.
12. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 5165-5171.
13. Smerdel MP, Steffensen KD, Waldstrøm M, et al. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol 2010; 118: 167-171.
14. Tanyi JL, McCann G, Hagemann AR, et al. Clinical predictors of bevacizumabassociated gastrointestinal perforation. Gynecol Oncol 2011; 120: 464-469.
15. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496.
16. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483.
17. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 2008; 26: 76-82.
18. McGonigle KF, Muntz HG, Vuky J, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. Cancer 2011; 117: 3731-3740.
19. Kudoh K, Takano M, Kouta H, et al. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecol Oncol 2011; 122: 233-237.
20. Micha JP, Goldstein BH, Rettenmaier MA, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2007; 17: 771-776.
21. Penson RT, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced Mullerian tumors. J Clin Oncol 2010; 28: 154-159.
22. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039-2045. The OCEANS trial showed a PFS advantage with the use of bevacizumab with carboplatin and gemcitabine in the setting of second-line platinum-sensitive disease.
23. Pujade-Lauraine E, Hilpert F, Weber B. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)- resistant recurrent ovarian cancer (OC). ASCO. Chicago. J Clin Oncol 2012; 2012:LBA5002. The AURELIA trial showed a PFS advantage with the use of bevacizumab in platinum-resistant ovarian cancer.
24. Aghajanian C, Nycum LR, Goff B, et al. Updated overall survival analysis in OCEANS, a randomized phase 3 trial of gemcitabine + carboplatin and bevacizumab or placebo followed by bevacizumab or placebo in platinumsensitive recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer; ESMO annual meeting; 2012. Vienna, 2012; abstr. 1578. This updated analysis shows no significant difference in the overall survival between the treatment arms at present.
25. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116: 2610-2621.
26. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326-5334.
27. Birrer MJ, Lankes H, Burger RA, et al. Biomarker (BM) results from GOG- 0218, a phase 3 trial of front-line bevacizumab (BV) and chemotherapy (CT) for ovarian cancer (OC) ESMO. Vienna, Austria: ESMO; 2012; p. 198.
28. Lambrechts D, Lenz H-J, de Haas S, et al. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 2013; 31: 1219-1230. A comprehensive review of predictive biomarkers for bevacizumab therapy.
29. Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012; 30: 362-371. This study demonstrates the clinical validity of the angiopoietin system as a target in ovarian cancer.
30. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after shortterm treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239.
31. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
32. Lu KV, Chang JP, Parachoniak CA, et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012; 22: 21-35.
33. Ayhan A, Ertunc D, Tok EC, et al. Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance. Int J Gynecol Cancer 2005; 15: 618-623.
34. Blumenschein GR, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol 2012; 30: 3287-3296.
35. Cole C, Lau S, Backen A, et al. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther 2010; 10: 495-504.
36. Whitworth MK, Backen AC, Clamp AR, et al. Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clin Cancer Res 2005; 11: 4282-4288.
37. Matei D, Emerson RE, Lai YC, et al. Autocrine activation of PDGFR[alpha] promotes the progression of ovarian cancer.Oncogene2006;25: 2060-2069.
38. Ben-Hamo R, Efroni S. Biomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies. BMC Syst Biol 2012; 6: 3-14.
39. Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006; 4: 1083-1087.
40. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting nonproductive angiogenesis. Nature 2006; 444: 1032-1037.
41. Coward J, Kulbe H, Chakravarty P, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011; 7: 6083-6096.
42. Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012; 366: 610-618.
43. Shahzad MMK, Arevalo JM, Armaiz-Pena GN, et al. Stress effects on FosBand interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 2010; 285: 35462-35470.
44. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 1331-1338.
45. Gonzalez-Martin A, Gladieff L, Tholander B, et al. Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC); Results from OCTAVIA ASCO; 2012. Chicago; 2012; abstr. 5017.
46. Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 2011; 11: 702-711.